alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
TREATIES AND OTHER INTERNATIONAL ACTS SERIES 09-1120 

________________________________________________________________________ 

DEFENSE 

Cooperation 

 Memorandum of Understanding 

Between the 

UNITED STATES OF AMERICA 

and AUSTRALIA 

Signed at Washington and Canberra 

November 12 and 20, 2009 

 with 

Annexes 

 
 NOTE BY THE DEPARTMENT OF STATE 

 Pursuant to Public Law 89—497, approved July 8, 1966 

(80 Stat. 271; 1 U.S.C. 113)—

“. . .the Treaties and Other International Acts Series issued 

under the authority of the Secretary of State shall be competent 

 evidence . . . of the treaties, international agreements other than 

treaties, and proclamations by the President of such treaties and 

international agreements other than treaties, as the case may be, 

therein contained, in all the courts of law and equity and of maritime 

jurisdiction, and in all the tribunals and public offices of the 

United States, and of the several States, without any further proof 

or authentication thereof.” 
 AUSTRALIA 

 Defense: Cooperation 

 Memorandum of understanding signed 

 at Washington and Canberra 

 November 12 and 20, 2009; 

 Entered into force November 20, 2009. 

 With annexes.
4R Reconstruction-Relocation 3R Maintenance-Resurfacing

$5.1M

$4.5M

FLAP Obligations/Expenditures by fiscal year

FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 TOTAL

$0 $1,674,476 $1,210,906 $826,905 $313,041 $2,684,588 $6,709,916

FLAP Loan/Credits by fiscal year

FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 TOTAL

($1,335,882) $0 $0 ($21,000) ($700,000) $2,900,000 $843,118

Programming Decisions Committee Members

Name Phone   E-mail Title

Shannon Scheffert 405-521-2553 ssheffert@fd9ns01.okladot.state.ok.us Local Government Division

Randy Robinson, PE 405-516-5319 randyr@okacco.com Assoc. of County Commissioners of OK

Chris Longley 720-963-3733 christopher.longley@dot.gov Access Program Manager

Call for Projects information

Start Date End Date

No. applications

received

Total Access funds

requested

5/30/2013 8/5/2013 11 $10,905,593

7/20/2015 10/16/2015 6 $4,627,000

Local Match

20.00%

Congressional District

OK-03

OK-02

OK-04

OK-01

Total project's costs by FLMA Accessed

USACE 57%

FWS 43%

Federal Lands Access Program (FLAP)

Oklahoma

Projects Programmed

6

FLAP Funds Programmed

$9.6M

Federal Lands Highway Division

CFLHD

FLAP Allocations by fiscal year

FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 TOTAL

$1,335,882 $1,345,917 $1,318,934 $1,003,146 $1,002,960 $1,174,697 $7,181,536

$16M

$2.8M

$2.7M

$2.4M

$1.7M
*This information is an overview of the FLAP projects information. It is subject to change at any time. For additional details or clarifications, please contact the Federal Lands Highway Division offices or visit the State FLAP 

webpage. 

Project ID Project Name- Description Improvement type Delivery Agency Delivery 

Year

OK FLAP 5407(1) BLACKGUM LANDING ROAD 3R Maintenance-Resurfacing Central Federal Lands Highway Division, FHWA 2021

OK FLAP 2460(1) CANTONMENT ROAD 3R Maintenance-Resurfacing Central Federal Lands Highway Division, FHWA 2018

OK FLAP 0600(1) WEKIWA ROAD 4R Reconstruction-Relocation Central Federal Lands Highway Division, FHWA 2018

OK FLAP CR S4200(1) BELLE STARR PARK ROAD 4R Reconstruction-Relocation Central Federal Lands Highway Division, FHWA 2014

OK FLAP CR E953(1) RIDGE ROUTE ROAD 4R Reconstruction-Relocation Central Federal Lands Highway Division, FHWA 2014

OK FLAP SH49(1) STATE HIGHWAY 49 4R Reconstruction-Relocation Central Federal Lands Highway Division, FHWA 2014
© 2018 HERE, © 2019 Microsoft Corporation

Project ID

OK FLAP 0600(1)

OK FLAP 2460(1)

OK FLAP 5407(1)

OK FLAP CR E953(1)

OK FLAP CR S4200(1)

OK FLAP SH49(1)
**Transcript: "Symptoms of P.A.D."**

Narrator: Even though P.A.D. can interfere with your day-to-day activities, many people who experience symptoms don't talk to their doctor about it. They think the discomfort is just an unfortunate but natural part of getting older. But there are certain signs and symptoms you can look for that can be an indication that you have P.A.D., and they start in your legs.

Rita: When you're walking, it's like a vice goes on your leg and it cramps it like that and it closes down until you absolutely cannot walk.

Mike: Your muscles actually tighten up on you and you just get to the point where you can't walk at all.

Rita: And I would come in from a walk in the winter and I'd get in the shower and the bottom soles of my feet were snow white. It was like there wasn't any blood there.

Narrator: So if you notice cramping or even fatigue or heaviness in the muscles of your legs, that could be P.A.D., especially if it happens when you walk or climb the stairs and goes away when you stop and rest. Also look for pain in your legs or feet that disturbs your sleep or color changes in your feet like paleness or blueness. You can have P.A.D. without having any symptoms of all. There is a simple test your doctor can give you called an ABI. It compares the blood pressure readings in your ankles with the blood pressure in your arms to help determine whether you have P.A.D. If you do, your doctor will talk to you about your options for staying in circulation either with lifestyle changes, medication, or perhaps surgery. And after treatment, things may start looking up.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 36 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                 S. 36

  To review domestic biopharmaceutical manufacturing capabilities in 
 order to improve public health and medical preparedness and response 
capabilities and domestic biopharmaceutical manufacturing capabilities.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

             January 24 (legislative day, January 3), 2023

 Mr. Rubio (for himself and Mr. Coons) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
  To review domestic biopharmaceutical manufacturing capabilities in 
 order to improve public health and medical preparedness and response 
capabilities and domestic biopharmaceutical manufacturing capabilities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Agility in Manufacturing 
Preparedness Act of 2023''.

SEC. 2. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MANUFACTURING 
              CAPABILITIES.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this section as the ``Secretary''), in cooperation with 
the Director of the Biomedical Advanced Research and Development 
Authority, shall seek to enter into an agreement with the National 
Institute for Innovation in Manufacturing Biopharmaceuticals to perform 
the services described in subsection (b).
    (b) Review and Recommendations.--Under an agreement described in 
subsection (a) between the Secretary, the Director of the Biomedical 
Advanced Research and Development Authority, and the National Institute 
for Innovation in Manufacturing Biopharmaceuticals, the National 
Institute for Innovation in Manufacturing Biopharmaceuticals shall--
            (1) review current domestic biopharmaceutical manufacturing 
        capacity at the Department of Health and Human Services and 
        such department's adaptability to various threats;
            (2) draft recommendations for developing, demonstrating, 
        deploying, and advancing new domestic biopharmaceutical 
        manufacturing technologies that address gaps identified under 
        paragraph (1) and align Federal technologies with technologies 
        available to the private sector, including through the new 
        BioMAP initiative of the Biomedical Advanced Research and 
        Development Authority; and
            (3) identify other opportunities and priorities to improve 
        the United States public health and medical preparedness and 
        response capabilities and domestic biopharmaceutical 
        manufacturing capabilities.
                                 <all>
```
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

MITCHELL LEE VARNELL,

Plaintiff

- Appellant,

v.

KENNETH SAWYER; et al.,

Defendants

- Appellees. No. 18

- 35771

D.C. No. 3:15

- cv

- 05443

- BHS

MEMORANDUM *

Appeal from the United States District Court for the Western District of Washington Benjamin H. Settle, District Judge, Presiding

Submitted June 2, 2020 * *

Before: LEAVY, PAEZ, and BENNETT, Circuit Judges.

Mitchell Lee Varnell, a Washington state prisoner, appeals pro se from the

district court’s summary judgment in his 42 U.S.C. § 1983 action alleging

deliberate indifference to his serious medical needs. We have jurisdiction under 28

U.S.C. § 1291. We rev iew de novo, Toguchi v. Chung , 391 F.3d 1051, 1056 (9 th

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36

- 3.

** The panel unanimously concludes this case is suitable for decision without oral argument. See Fed. R. App. P. 34(a)(2). 

# FILED

JUN 5 2020

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS2 18

- 35771

Cir. 2004), and we affirm.

The district court properly granted summary judgment because Varnell

failed to raise a genuine dispute of material fact as to whether defendants were

deliberately indifferen t to Varnell ’s serious medical needs regarding his back

. See

id. at 1057

- 60 (a prison official is deliberately indifferent only if he or she knows

of and disregards an excessive risk to inmate health; medical malpract ice,

negligence, or a difference of opinion concerning the course of treatment does not

amount to deliberate indifference); see also Hallett v. Morgan

, 296 F.3d 732, 746

(9 th Cir. 2002) ( delays in medical treatment do not constitute an Eighth

Amendment violation unless the defendants know that “delays would cause

significant harm” ).

We do not consider documents not presented to the district court. See

United States v. Elias , 921 F.2d 870, 874 (9th Cir. 1990).

We do not consider matters not specifically and distinctly raised and argued

in the opening brief. Padgett v. Wright , 587 F.3 d 983, 985 n. 2 (9 th Cir. 2009).

Varnell’s request for appointment of counsel , set forth in the opening brief,

is denied.

AFFIRMED.
II 

118TH CONGRESS 

1ST SESSION S. 2912 

To amend the Indian Self-Determination and Education Assistance Act to 

allow the Secretary of Agriculture to enter into self-determination contracts with Indian Tribes and Tribal organizations to carry out supplemental nutrition assistance programs. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 21, 2023 

Ms. SMITH (for herself and Mr. ROUNDS) introduced the following bill; which 

was read twice and referred to the Committee on Indian Affairs 

A BILL 

To amend the Indian Self-Determination and Education Assistance Act to allow the Secretary of Agriculture to 

enter into self-determination contracts with Indian Tribes 

and Tribal organizations to carry out supplemental nutrition assistance programs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘SNAP Tribal Food 

5 Sovereignty Act of 2023’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•S 2912 IS

1 SEC. 2. SELF-DETERMINATION FOR SNAP. 

2 Title I of the Indian Self-Determination and Edu3 cation Assistance Act (25 U.S.C. 5321 et seq.) is amended 

4 by adding at the end the following: 

5 ‘‘SEC. 112. SELF-DETERMINATION FOR SNAP. 

6 ‘‘(a) AGRICULTURE SELF-DETERMINATION AUTHOR7 IZED.—The Secretary of Agriculture shall enter into self8 determination contracts, in accordance with subsection 

9 (b), with Indian Tribes and Tribal organizations, on the 

10 request of any Indian Tribe by Tribal resolution, to plan, 

11 conduct, and administer any function, service, or activity 

12 of the supplemental nutrition assistance program estab13 lished under the Food and Nutrition Act of 2008 (7 

14 U.S.C. 2011 et seq.) for the Indian Tribe. 

15 ‘‘(b) SELF-DETERMINATION CONTRACT.—A self-de16 termination contract entered into under subsection (a) 

17 shall have the same terms and conditions, and be subject 

18 to the same procedures, regulations, and requirements, as 

19 a self-determination contract entered into under section 

20 102, except that the Secretary of Agriculture and the De21 partment of Agriculture shall be the appropriate Secretary 

22 and agency for purposes of a self-determination contract 

23 entered into under subsection (a). 

24 ‘‘(c) TECHNICAL ASSISTANCE.—The Office of Self25 Governance of the Bureau of Indian Affairs shall provide 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•S 2912 IS

1 technical assistance regarding the self-determination con2 tracts authorized under this section to— 

3 ‘‘(1) the Secretary of Agriculture; and 

4 ‘‘(2) Indian Tribes and Tribal organizations 

5 that request that assistance.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
[Federal Register Volume 62, Number 205 (Thursday, October 23, 1997)]
[Notices]
[Page 55283]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-28114]


-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Special Emphasis Panel in Bioengineering and Environmental 
Systems; Notice of Meeting

    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463, as amended), the National Science Foundation announces the 
following meeting.

    Name: Special Emphasis Panel in Bioengineering and Environmental 
Systems (No. 1189).
    Date and Time: November 12-14, 1997; 8:00am--6:00pm.
    Place: National Science Foundation, 4201 Wilson Boulevard, Rooms 
380 and 530 Arlington, VA 22230.
    Type of Meeting: Closed.
    Contact Person: H. Frederick Bowman, Program Director, 
Biomedical Engineering and Research to Aid Persons with 
Disabilities, Division of Bioengineering and Environmental Systems, 
National Science Foundation, 4210 Wilson Boulevard, Arlington, VA 
22230, Telephone: (703) 306-1318.
    Purpose of Meeting: To provide advice and recommendations 
concerning proposals submitted to NSF for financial support.
    Agenda: To review and evaluate proposals as part of the selection 
process for awards.
    Reason for Closing: The proposals being reviewed include 
information of a proprietary or confidential nature, including 
technical information; financial data, such as salaries; and 
personal information concerning individuals associated with the 
proposals. These matters are exempt under 5 U.S.C. 552b(c), (4) and 
(6) of the Government in the Sunshine Act.
M. Rebecca Winkler,
Committee Management Officer.
[FR Doc. 97-28114 Filed 10-22-97; 8:45 am]
BILLING CODE 7555-01-M
EXHIBIT 10.3



                           UNITED STATES LEATHER, INC.

                         Executive Equity Ownership Plan


             The primary objective of the Company's senior management group
   is to expeditiously create the return of USL as a successful and
   preeminent competitor in the global leather business.  This should enable
   the Company at some future date to be sold by the current owners at an
   acceptable sale price.  Recognizing that the senior management group may
   desire to participate in the purchase of the Company, it is the Board's
   desire to provide special financial recognition to senior management
   members should that opportunity arise.  This special financial recognition
   would be directly linked to annual Executive Incentive Compensation Plan
   performance as follows:

   I.   Participants

             Employees specifically designed by the Board will be
   participants.

   II.  Generation of Special Financial Recognition

             An annual payout must be generated by the Company's Executive
   Incentive Compensation Plan ("Incentive Award") in order for any award
   under the Equity Ownership Plan ("Special Award") to occur.  For every
   dollar of Incentive Award to a participant, he/she will be credited with
   additional dollars of Special Award as follows:

                  Equity Value             Special Award

                  $75 Million         1X Deferred Annual Awards

                  $95 Million         2X Deferred Annual Awards

   III. Participant's Obligations

             In order to qualify for Special Awards, the participant must be
   willing to (i) defer all or part of the annual Incentive Award due them
   for a maximum of three years and must be willing to forfeit this award
   should he/she leave the Company voluntarily during the deferral period,
   and (ii) invest both the Incentive Awards and the Special Awards in the
   Company at the time of its sale.

   IV.  Interest on Deferred Awards

             The Company will credit deferral accounts with interest at the
   compounded rate of 10% per annum.

   <PAGE>
                         EXECUTIVE EQUITY OWNERSHIP PLAN

                                  PARTICIPANTS


        Sr. VP Manufacturing

        Dir. Operations - MKE

        Dir. Operations - N.C.

        Dir. Operations - Omaha

        Sr. VP Sales

        VP Sales - Furniture

        VP Sales - MKE

        VP Sales & Contract Admin.

        CFO

        VP Human Resources
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 3542 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                S. 3542

   To amend the Atchafalaya National Heritage Area Act to modify the 
   boundary of the Atchafalaya National Heritage Area, and for other 
                               purposes.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           December 14, 2023

  Mr. Cassidy (for himself and Mr. Kennedy) introduced the following 
bill; which was read twice and referred to the Committee on Energy and 
                           Natural Resources

_______________________________________________________________________

                                 A BILL

 
   To amend the Atchafalaya National Heritage Area Act to modify the 
   boundary of the Atchafalaya National Heritage Area, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Atchafalaya National Heritage Area 
Boundary Modification Act''.

SEC. 2. ATCHAFALAYA NATIONAL HERITAGE AREA BOUNDARY MODIFICATION.

    (a) Boundaries.--Section 213(b) of the Atchafalaya National 
Heritage Area Act (54 U.S.C. 120102 note; Public Law 109-338; 120 Stat. 
1791) is amended by striking ``and Ascension'' and inserting 
``Ascension, and Lafourche''.
    (b) Composition of Local Coordinating Entity.--Section 213(c)(2) of 
the Atchafalaya National Heritage Area Act (54 U.S.C. 120102 note; 
Public Law 109-338; 120 Stat. 1791) is amended by striking ``14'' and 
inserting ``15''.
                                 <all>
```
# L_2005266EN.01005901.xml

| 11.10.2005 | EN | Official Journal of the European Union | L 266/59 |
| --- | --- | --- | --- |

11.10.2005

EN

Official Journal of the European Union

L 266/59

---

COUNCIL DECISION

of 20 September 2005

on the conclusion of a Protocol to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the Kingdom of Morocco, of the other part, to take account of the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the European Union

(2005/695/EC)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 310 in conjunction with the second sentence of the first subparagraph of Article 300(2) and the second subparagraph of Article 300(3) thereof,

Having regard to the 2003 Act of Accession, and in particular to Article 6(2) thereof,

Having regard to the proposal from the Commission,

Having regard to the assent of the European Parliament (1),

Whereas:

| (1) | The Protocol to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the Kingdom of Morocco, of the other part, was signed on behalf of the European Community and its Member States on 31 May 2005. |
| --- | --- |

(1)

The Protocol to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the Kingdom of Morocco, of the other part, was signed on behalf of the European Community and its Member States on 31 May 2005.

| (2) | The Protocol should be approved, |
| --- | --- |

(2)

The Protocol should be approved,

HAS DECIDED AS FOLLOWS:

Sole Article

The Protocol to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the Kingdom of Morocco, of the other part, to take account of the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the European Union, is hereby approved on behalf of the European Community and its Member States.

The text of the Protocol is attached to this Decision (2).

Done at Brussels, 20 September 2005.

For the Council

The President

M. BECKETT

---

(1)  Opinion delivered on 6 September 2005 (not yet published in the Official Journal).

1

(2)  
  OJ L 242, 19.9.2005, p. 2.

2

---